Capsida Natural History Study for STXBP1

Written By Charlene Rigby

We are thrilled that the Natural History Study sponsored by Capsida Biotherapeutics has been posted on ClinicalTrials.gov.

“This is a prospective, non-interventional, longitudinal study designed to characterize the natural history of STXBP1 related encephalopathy with epilepsy, in participants ≤5 years of age.”

  • Natural history study. Natural history studies are important research studies that examine how a disease changes over time in a patient population. They allow a better understanding of a disease process over time to help develop better treatments.

  • Prospective, non-interventional, longitudinal study. The study is a prospective, longitudinal study meaning data is collected over time. This is a “non-interventional”, or observational, study so participants will not receive therapies as part of this study.

Dr. Alana Salvucci, MD, Medical Director of Clinical Development at Capsida Biotherapeutics, will be speaking at the STXBP1 Summit+ on 20 August 2022, to provide more information on this natural history study sponsored by Capsida.

For more information on the study:

Charlene Rigby
Previous

Camden Different
Next

Report on FDA Listening Session on STXBP1